Avantor, Inc. (NYSE:AVTR) Stock Has Consensus Price Target of $14.77

Avantor, Inc. (NYSE:AVTR) has received an average recommendation of “Hold” from the sixteen brokerages that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and two have given a buy rating to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $14.77.

A number of brokerages have recently commented on AVTR. Wells Fargo & Company boosted their price target on Avantor from $14.00 to $16.00 and gave the stock an “overweight” rating in a research report on Thursday, July 30th. TD Cowen raised their price target on Avantor from $15.00 to $17.00 and gave the company a “hold” rating in a report on Tuesday, October 13th. Royal Bank Of Canada upped their price target on shares of Avantor from $14.00 to $17.00 and gave the stock a “sector perform” rating in a research note on Wednesday, October 28th. Robert W. Baird increased their price objective on shares of Avantor from $17.00 to $18.00 and gave the company an “outperform” rating in a research report on Thursday, October 29th. Finally, Evercore set a $17.00 target price on shares of Avantor in a research note on Wednesday, October 28th.

Avantor Trading Down 3.2%

NYSE AVTR opened at $15.14 on Friday. The stock’s 50 day moving average is $15.58 and its 200 day moving average is $11.31. The company has a quick ratio of 1.27, a current ratio of 1.89 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $10.26 billion, a PE ratio of 19.08, a P/E/G ratio of 7.08 and a beta of 0.95. Avantor has a twelve month low of $7.26 and a twelve month high of $17.45.

Avantor (NYSE:AVTR) last released its earnings results on Wednesday, October 28th. The company reported $0.22 earnings per share for the quarter, topping analysts’ consensus estimates of $0.21 by $0.01. The firm had revenue of $1.70 billion for the quarter, compared to the consensus estimate of $1.64 billion. Avantor had a net margin of 5.08% and a return on equity of 9.79%. The company’s revenue was up 4.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.22 EPS. Research analysts forecast that Avantor will post 0.82 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Avantor

Large investors have recently bought and sold shares of the business. Parallel Advisors LLC raised its holdings in shares of Avantor by 3.8% during the 3rd quarter. Parallel Advisors LLC now owns 19,033 shares of the company’s stock worth $286,000 after acquiring an additional 693 shares in the last quarter. Allspring Global Investments Holdings LLC grew its stake in shares of Avantor by 7.8% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 13,253 shares of the company’s stock worth $199,000 after buying an additional 957 shares in the last quarter. Elevation Wealth Partners LLC increased its holdings in shares of Avantor by 72.3% in the 3rd quarter. Elevation Wealth Partners LLC now owns 2,803 shares of the company’s stock worth $42,000 after buying an additional 1,176 shares during the last quarter. Nisa Investment Advisors LLC lifted its holdings in shares of Avantor by 40.8% in the 3rd quarter. Nisa Investment Advisors LLC now owns 4,938 shares of the company’s stock valued at $74,000 after acquiring an additional 1,431 shares during the last quarter. Finally, Sage Rhino Capital LLC lifted its holdings in shares of Avantor by 17.1% in the 3rd quarter. Sage Rhino Capital LLC now owns 13,060 shares of the company’s stock valued at $197,000 after acquiring an additional 1,903 shares during the last quarter. 95.08% of the stock is currently owned by institutional investors.

About Avantor

Avantor, Inc is a global provider of mission-critical products and services used in the life sciences, healthcare, education, and advanced technology industries. The company supplies chemicals, reagents, laboratory consumables, equipment, and other materials used in research, development, manufacturing, and quality-control activities.

Avantor also provides specialized solutions for biopharmaceutical production, including materials and services that support drug development, biologics manufacturing, and other bioprocessing applications.